Efficacy of total oral regimens containing ixazomib in patients with relapsed and refractory multiple myeloma
10.3760/cma.j.cn112138-20210117-00045
- VernacularTitle:伊沙佐米全口服方案治疗复发难治多发性骨髓瘤的疗效分析
- Author:
Jing WANG
1
;
Jingjing SHANG
;
Song JIN
;
Ying YAO
;
Zhi YAN
;
Depei WU
;
Zhengzheng FU
Author Information
1. 苏州弘慈血液病医院血液科，苏州 215128
- Keywords:
Multiple myeloma;
Treatment outcome;
Safety;
Ixazomib
- From:
Chinese Journal of Internal Medicine
2022;61(1):95-98
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the efficacy and safety of total oral regimen containing ixazomib in multidrug-resistant relapsed and refractory multiple myeloma(RRMM). A total of 38 patients were retrospectively analyzed from August 2018 to January 2020 in the First Affiliated Hospital of Soochow University. The overall response rate (ORR)was 36.8%. Among them, the very good partial response (VGPR) or better rate was 23.7%, and the complete response (CR) rate was 5.3%. The ORR was 41.7% in patients receiving ixazomib-lenalidomide-dexamethasone (IRD) regimen. Median PFS was 5 months and median OS was 7.5 months. The ORR was 50% after second-line therapy, 40% after third-line therapy and 12.5% after forth-line therapy or more. The ORR was 29.0% in bortezomib-refractory patients, 38.0% in lenalidomide-refractory patients, 21.4% in bortezmoib & lenalidomide dual refractory patients. Grade 3-4 hematological adverse events (AEs) were reported in 21% patients. Common hematological AEs included lymphopenia, neutropenia, thrombocytopenia. Other usual AEs were fatigue and diarrhea. No grade 3-4 peripheral neuropathy was recorded. In the treatment of relapsed/refractory multiple myeloma patients with multidrug resistance, the total oral regimens containing ixazomib demonstrate reliable efficacy and safety. Early administration of ixazomib at first or second relapse is suggested for more favorable clinical outcome.
